PHARMACEUTICALS related term(s) Drugs

Addresses

State of the Union: President Biden, S891–S896 [1MR], H1200–H1206 [1MR]

Amendments

Dept. of HHS: establish Advanced Research Projects Agency-Health (H.R. 5585), H5802 [22JN]

——— establish Advanced Research Projects Agency-Health (H.R. 5585), consideration (H. Res. 1191), H5750 [22JN]

Diseases and disorders: making supplemental appropriations for coronavirus emergency response and relief (H.R. 7007), consideration (H. Res. 973), H1393 [9MR]

Drugs: establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), S5094 [27SE], S5148, S5247, S5254, S5312, S5335, S5398, S5506 [28SE], S5518 [29SE], H8331 [30SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), consideration (H. Res. 1017), H4031 [31MR]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), consideration of Senate amendment (H. Res. 1404), H8329 [30SE]

——— streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (S. 253), S1781 [24MR]

Economy: use of budget reconciliation to fight inflation, reduce prescription drug and health care costs, address climate change, increase tax fairness, and reduce deficit (H.R. 5376), S3922 [3AU], S4070, S4145, S4170, S4171, S4172, S4178, S4179, S4180, S4181, S4184, S4185, S4186, S4187, S4190, S4191, S4192, S4197, S4199, S4200, S4221, S4222, S4225, S4226, S4231, S4234, S4237, S4238, S4243, S4244, S4245, S4247, S4248, S4249, S4250, S4252, S4253, S4256, S4257, S4292, S4295, S4296, S4297, S4298, S4301, S4306, S4310, S4311, S4312, S4313, S4316, S4317, S4320, S4321, S4322, S4323, S4324, S4325, S4326, S4327, S4329, S4331, S4334, S4335, S4336, S4337, S4338, S4339, S4341, S4342, S4343, S4344, S4345, S4346, S4347, S4348, S4349, S4350, S4360, S4361, S4376, S4397, S4399 [6AU], H7577 [12AU]

Analyses

Americans Don’t Support Surrendering Innovation for Democrats’ Drug Price Controls: Committee on Ways and Means (House) Republican staff, H7675 [12AU]

Inflation Reduction Act Budgetary and Macroeconomic Effects: University of Pennsylvania Wharton School, H7670 [12AU]

Articles and editorials

After Roe, Urgent Questions About Cancer Care, S3622–S3624 [25JY]

Americans Give Health Care System Failing Mark—AP-NORC Poll, S4554 [13SE]

5 Gimmicks in Democrats’ Reconciliation Bill, H7675 [12AU]

For Older Americans, Health Bill Will Bring Savings and ‘Peace of Mind’, H7567 [12AU]

Insulin Copay Cap Passes House Hurdle, But Senate Looks for a Broader Bill, H7676 [12AU]

Myths About Fentanyl Persist as Opioid Continues To Cause Overdose Deaths, H8749 [5DE]

Opioid Epidemic Is Surging Among Black People Because of Unequal Access to Treatment, H8747–H8749 [5DE]

Over 230 Economists Warn Manchin’s Spending Bill Will Perpetuate Inflation, H7650 [12AU]

UnitedHealthcare Pays Providers Below Standard Rates for Covid–19 Vaccines, S376 [20JA]

Bills and resolutions

Abortion: preempt State restrictions on dispensing mifepristone or misoprostol (see H.R. 8976), H8112 [22SE]

——— prohibit declaration of national emergency relative to abortion (see S. 4474), S3159 [23JN]

American Rescue Plan Act: rescind certain amounts appropriated to reduce national debt (see H.R. 7699), H4796 [10MY]

Armed Forces: establish certain protections for members who refuse to receive vaccinations against coronavirus (see H.R. 7570), H4458 [25AP]

——— establish certain protections for members who refuse to receive vaccinations against coronavirus and increase basic pay for members of uniformed services (see H.R. 6429), H252 [19JA]

——— modify treatment of certain controlled substance violations under Uniform Code of Military Justice (see H.R. 7446), H4431 [7AP]

——— preserve readiness by limiting separations based on coronavirus vaccination status and continuing pay and benefits for members while religious and health accommodations are pending (see S. 4925), S4969 [22SE]

——— prohibit adverse action toward members who refuse to receive coronavirus vaccine (see H.R. 6649), H1074 [8FE]

——— reinstate servicemembers involuntarily separated solely due to refusal to receive vaccination against coronavirus (see H.R. 6633), H1013 [7FE]

Business and industry: prohibit manufacturers from interfering with therapeutically equivalent or interchangeable substitutions by health care providers to limit competition from generic drug or biosimilar biological products (see H.R. 7473), H4432 [7AP]

Centers for Medicare & Medicaid Services: provide guidance regarding coverage of prescription digital therapeutics under Medicaid and State Children’s Health Insurance Program (see S. 5238), S7101 [12DE]

Contraceptives: preempt State bans on prescription, provision, or use of drug, biological product, or device for contraception if approved, licensed, cleared, or otherwise authorized for human use by FDA for contraception (see H.R. 8421), H6882 [19JY]

Controlled Substances Act: amend to fix technical error in definitions (see S. 4235), S2544 [17MY] (see H.R. 9178), H8395 [14OC]

Courts: permit civil actions against U.S. or any State or local government entity for coronavirus vaccination mandates (see H.R. 6811), H1139 [22FE]

Crime: prohibit health care providers from administering coronavirus vaccines to minors without parental consent (see H.R. 6676), H1112 [9FE]

DEA: make permanent scheduling of fentanyl-related substances (see H.R. 6713), H1119 [11FE]

——— modify registration requirements relative to research with controlled substances (see S. 5123), S6779 [17NO]

——— provide for life imprisonment for certain offenses involving fentanyl (see H.R. 6439), H288 [20JA]

——— require removal of drug from scheduling within certain period pursuant to recommendation of Dept. of HHS (see H.R. 8931), H8064 [21SE]

Dept. of Defense: implement Inspector General recommendations relative to mitigation of foreign suppliers in pharmaceutical supply chain (see H.R. 6374), H77 [12JA]

——— modify limitation on discharge of Armed Forces members solely on basis of failure to obey lawful order to receive coronairus vaccine (see H.R. 7936), H5232 [3JN]

Dept. of Education: prohibit Federal funding to local educational agency requiring any student at schools served by agency to wear face covering or be vaccinated against coronavirus (see H.R. 6456), H288 [20JA]

Dept. of HHS: allow women greater access to safe and effective oral contraceptive drugs intended for routine use (see S. 4638), S3743 [27JY] (see H.R. 8428), H6882 [19JY]

——— amend Health Resources and Services Administration Counter Measure Injury Compensation Program relative to coronavirus vaccines (see S. 3810), S1119 [10MR]

——— amend Public Health Service Act relative to determinations regarding certain biosimilar application elements (see H.R. 7047), H1423 [9MR]

——— award grants, contracts, or cooperative agreements to facilitate funding of community-based mental health and substance use disorder services and peer support programs (see S. 3688), S785 [17FE]

——— clarify conditions to approve generic drug applications with labeling temporarily different than brand name drug (see S. 4351), S2785 [6JN] (see H.R. 6973), H1372 [8MR]

——— collect and disseminate information on pharmaceutical affordability assistance programs to consumers and health facilities (see S. 4481), S3159 [23JN]

——— conduct demonstration program to test providing preferential treatment under Medicare, Medicaid, and Children’s Health Insurance Program for certain drugs and biologicals manufactured in U.S. (see S. 3991), S1980 [5AP] (see H.R. 7400), H4190 [5AP]

——— contract with third-party organizations to carry out independent value assessments for approved drugs (see H.R. 9321), H8541 [16NO]

——— disapprove rule entitled ‘‘Vaccine and Mask Requirements To Mitigate the Spread of COVID–19 in Head Start Programs’’ (see S.J. Res. 39), S674 [14FE] (see H.J. Res. 81), H4453 [21AP]

——— enhance efforts to address antibiotic resistance (see H.R. 9094), H8370 [30SE]

——— ensure certain Native American facilities receive items from strategic national stockpile and qualified pandemic or epidemic products (see S. 3444), S49 [5JA] (see H.R. 6372), H43 [11JA]

——— establish Advanced Research Projects Agency-Health (H.R. 5585), consideration (see H. Res. 1191), H5733 [21JN]

——— establish automated supply-chain tracking application that provides near real-time insight into amount of critical medical and health supplies available in strategic national stockpile (see H.R. 6520), H307 [28JA]

——— establish fentanyl lethality awareness campaign, establish Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs, and provide grants to mitigate effects of drug misuse (see S. 4358), S2865 [8JN] (see H.R. 9221), H8409 [21OC]

——— evaluate process by which interchangeable biological products are approved to be used in pharmaceuticals (see H.R. 8877), H7964 [19SE]

——— expand opioid overdose reversal medication access, education, and co-prescribing grant programs (see S. 4794), S4479 [7SE]

——— grant eligible researchers access to drugs or biologic products at discounted price for qualified research (see S. 4026), S2091 (see S. 4053), S2092 [7AP] (see H.R. 7472), H4432 [7AP]

——— improve domestic manufacturing surge capacity and capabilities for biodefense and pandemic preparedness (see S. 3588), S546 [7FE]

——— improve inspections of foreign drug manufacturing establishments (see H.R. 7006), H1421 [9MR]

——— improve operation of Organ Procurement and Transplantation Network (see S. 5314), S9625 [20DE]

——— increase unannounced inspections of foreign human drug establishments and evaluate differences between domestic and foreign establishments, including impact of advanced notice to establishment owners (see H.R. 6980), H1373 [8MR]

——— issue guidance on strategies under Medicaid and Children’s Health Insurance Program to increase mental health and substance use disorder care provider education, training, recruitment, and retention (see S. 5043), S5542 [29SE]

——— maintain list of country of origin of all drugs marketed in U.S. and ban use of Federal funds for purchase of drugs manufactured in China (see H.R. 7121), H3826 [17MR]

——— prevent and address misuse of opioids and other drugs commonly used in pain management or injury recovery by students and student athletes (see S. 3940), S1803 [28MR] (see H.R. 7246), H3895 [28MR]

——— prohibit discrimination and preferential treatment on basis of race, color, or national origin in administration of health programs (see H.R. 6463), H288 [20JA]

——— prohibit from placing any coronavirus vaccine on child and adolescent immunization schedule without posting all clinical data on safety and efficacy of such vaccine (see S. 5171), S6941 [1DE] (see H.R. 9404), H8729 [2DE]

——— prohibit Organ Procurement and Transplantation Network from requesting coronavirus vaccination status of individuals for national list of individuals who need organs (see H.R. 6540), H329 [1FE]

——— provide for appropriate cost-sharing for insulin products covered under Medicare part D and private health plans (see S. 3700), S786 [17FE]

——— provide for designation of institutions of higher education as Centers of Excellence in Cannabis Research (see H.R. 8540), H7255 [27JY]

——— provide grants to medical and other health professional schools to expand or develop education and training programs for substance use prevention and treatment (see H.R. 9007), H8220 [28SE]

——— reauthorize and expand grant program for State and Tribal response to opioid and stimulant use and misuse (see S. 4839), S4575 [13SE]

——— reauthorize and improve block grants for prevention and treatment of substance abuse (see S. 4301), S2708 [25MY]

——— reauthorize certain programs to reduce opioid overdose deaths (see H.R. 7681), H4721 [6MY]

——— reauthorize grant program for screening, assessment, and treatment services for maternal mental health and substance use disorders (see S. 3824), S1153 [14MR] (see H.R. 7073), H3742 [15MR]

——— report on interoperability of medical devices (see H.R. 9067), H8315 [29SE]

——— request President and direct Sec. of HHS to transmit documents to House of Representatives relative to any coronavirus vaccine (see H. Res. 1244), H7066 [21JY]

——— request President and direct Sec. of HHS to transmit documents to House of Representatives relative to ivermectin (see H. Res. 1355), H7882 [15SE]

——— require drug manufacturers to include printed inserts containing drug information when they ship their products to pharmacies (see H.R. 6519), H307 [28JA]

——— require Inspector General investigation and report on Vaccine Adverse Event Reporting System (see H.R. 7308), H4071 [31MR]

——— revise opioid treatment program admission criteria to eliminate requirement that patients have been addicted for at least 1 year prior to being admitted for treatment (see H.R. 7238), H3894 [28MR]

——— support endemic fungal disease research, incentivize valley fever vaccine development, and discover new antifungal therapies and diagnostics to fight infections such as Valley Fever (see S. 3498), S220 [13JA]

——— update National Action Plan for Adverse Drug Event Prevention to provide information on adverse drug events and pharmacogenomic testing and improve electronic health records for pharmacogenomic information (see H.R. 6875), H1176 [28FE]

Dept. of Homeland Security: prohibit from requiring coronavirus vaccination for essential critical infrastructure workers crossing border (see S. 3694), S785 [17FE]

——— restrict flow of illicit drugs into U.S. (see S. 4645), S3743 [27JY] (see H.R. 9050), H8314 [29SE]

Dept. of Justice: provide for Comprehensive Opioid, Stimulant, and Substance Abuse Program pilot program for local law enforcement agencies in rural areas to purchase naloxone to prevent and reduce opioid overdose deaths (see H.R. 6593), H947 [3FE]

——— register practitioners to transport controlled substances to States in which practitioner is not registered to administer substances at places outside of principal places of business (see H.R. 7259), H3895 [28MR]

——— require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances (see S. 4858), S4638 [15SE]

Dept. of Labor: require action plan within Workforce Innovation and Opportunity Act one-stop delivery system to meet needs of individuals who have experienced trauma, mental health challenges, or substance use disorder (see H.R. 7921), H5227 [31MY]

Dept. of Veterans Affairs: expand access to Veterans Community Care Program to include certain veterans seeking mental health or substance-use services and toxic-exposed veterans (see S. 5348), S9779 [21DE]

Depts. of HHS and State: formulate strategy to secure support from foreign countries, multilateral organizations, and others to facilitate development and commercialization of qualified pandemic or epidemic products (see H.R. 9303), H8507 [15NO]

Disasters: streamline sharing of information among Federal disaster assistance agencies, expedite delivery of life-saving assistance to survivors, speed recovery of communities, and protect privacy of survivors (see S. 4599), S3612 [21JY]

Diseases and disorders: end coronavirus lockdowns and vaccine mandates (see H.R. 9054), H8314 [29SE]

——— improve research and development of medical countermeasures for novel pathogens (see S. 3496), S220 [13JA]

——— making supplemental appropriations for coronavirus emergency response and relief (see H.R. 7007), H1421 [9MR]

——— making supplemental appropriations for coronavirus emergency response and relief (H.R. 7007), consideration (see H. Res. 973), H1421 [9MR]

——— prepare for, and respond to, existing viruses, emerging new threats, and pandemics (see S. 3799), S1118 [10MR]

——— prohibit Federal Government from limiting State access to key therapies and from prioritizing Federal contracts over State contracts relative to purchasing supplies to combat coronavirus pandemic (see S. 3440), S23 [4JA] (see H.R. 6832), H1145 [25FE]

——— prohibit transplant centers from discriminating against individual seeking organ due to whether individual is vaccinated against coronavirus (see H.R. 6534), H329 [1FE]

——— prohibit vaccination mandates for coronavirus (see H.R. 6395), H193 [13JA]

——— protect against seasonal and pandemic influenza (see H.R. 9476), H8873 [8DE]

——— raise awareness about cancer chordoma (see H. Res. 1514), H8874 [8DE]

——— support continued investment to complete development of HIV vaccine (see H. Res. 1506), H8709 [1DE]

——— terminate existing Federal coronavirus face covering and vaccine mandates (see H.R. 7423), H4396 [6AP]

District of Columbia: nullify order of Mayor imposing vaccine entry requirement for certain establishments and facilities (see H.R. 6382), H77 [12JA]

——— prohibit use of Federal and local funds for coronavirus vaccine mandate in District of Columbia schools and repeal related legislation enacted by District of Columbia Council (see S. 4818), S4541 [12SE]

Drugs: address foreign production of precursor chemicals used for illicit production of narcotics and psychotropic drugs and other controlled substances (see S. 4315), S2751 [26MY]

——— allow persons authorized to collect controlled substances for destruction through consumer return program to open and inspect packages and transport drugs to another location for destruction (see H.R. 6896), H1274 [2MR]

——— allow sponsors of certain new drug applications to rely on investigations conducted in certain foreign countries (see S. 3576), S523 [3FE]

——— combat fentanyl crisis (see S. 4782), S4045 [4AU]

——— direct President to provide documents to House of Representatives relative to communications with several agencies on recommendations to reduce availability of illicitly manufactured fentanyl-related substances (see H. Res. 1274), H7170 [26JY]

——— establish requirements relative to cost-sharing for certain insulin products (see H.R. 6833), H1145 [25FE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), consideration (see H. Res. 1017), H4071 [31MR]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), consideration of Senate amendment (see H. Res. 1404), H8313 [29SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), correction in enrollment (see S. Con. Res. 45), S5543 [29SE]

——— express that fentanyl-related substances are a weapon of mass destruction and should be classified as such (see H. Res. 1327), H7727 [26AU]

——— improve patient access to emerging medication therapies by clarifying scope of permitted communications between biopharmaceutical manufacturers and population health decision makers (see H.R. 7008), H1421 [9MR] (see H.R. 9297), H8507 [15NO]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 9679), H10055 [22DE]

——— mitigate effects of coronavirus pandemic on incentives for development of orphan drugs (see H.R. 8641), H7544 [2AU]

——— modernize process of accelerated approval of drugs for serious or life-threatening diseases or conditions (see S. 4446), S3075 [22JN]

——— prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (see S. 4151), S2358 [5MY] (see H.R. 8175), H5822 [22JN]

——— prohibit deceptive sale of fentanyl (see S. 4984), S5225 [28SE]

——— prohibit delivery of opioids by means of dark web (see S. 3782), S1059 [8MR] (see H.R. 7300), H4006 [30MR]

——— prohibit Federal funding for any State, local, Tribal, or private entity that operates or controls injection center in violation of Controlled Substances Act (see H.R. 7029), H1422 [9MR]

——— prohibit imposition of certain substantial burdens relative to coronavirus vaccine mandates on religious exercise (see S. 4163), S2381 [9MY]

——— provide for lower prices through drug price negotiation (see H.R. 7497), H4438 [11AP]

——— provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage (see H.R. 8988), H8119 [26SE]

——— reauthorize program of grants and contracts for development of drugs for rare diseases and conditions (commonly known as ‘‘orphan drugs’’) (see H.R. 7640), H4712 [3MY]

——— streamline, coordinate, and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (see H.R. 8454), H7065 [21JY]

FDA: accelerate approval of products for serious or life-threatening diseases or conditions (see H.R. 6996), H1373 [8MR]

——— allow digital communication of prescribing information for drugs, including biological products (see H.R. 7559), H4453 [21AP]

——— allow for alternatives to animal testing for purposes of drug and biological product applications (see S. 5002), S5540 [29SE]

——— allow manufacturers and sponsors of drugs to use alternative testing methods to animal testing to investigate safety and effectiveness of biological products (see S. 4288), S2620 [19MY]

——— amend process informing persons submitting abbreviated application for new drug whether new drug is qualitatively or quantitatively same as listed drug (see H.R. 7032), H1422 [9MR]

——— authorize program to support adoption of, and improve development of, innovative approaches to pharmaceutical product design and manufacturing (see H.R. 6988), H1373 [8MR]

——— clarify reporting requirements for establishments within foreign country engaged in manufacture, preparation, propagation, compounding, or processing of active pharmaceutical ingredients (see H.R. 6483), H300 [25JA]

——— deem certain regulated products as drugs (see S. 4333), S2752 [26MY]

——— deny approval of new drug application for opioid analgesic drug on basis of such drug not being clincally superior to other commercially available drugs (see S. 4340), S2752 [26MY] (see H.R. 8586), H7405 [28JY]

——— enhance data reporting on clinical trial demographics and provide resources to improve access to clinical trials in underrepresented communities (see H.R. 6584), H946 [3FE]

——— establish process to allow holders of abbreviated new generic drug applications to make labeling changes to include new or updated safety-related information (see H.R. 9011), H8220 [28SE]

——— expand certain authorities relative to recall of controlled substances to apply with respect to all drugs (see H.R. 6545), H330 [1FE]

——— express that process behind Operation Warp Speed should be integrated within operations (see H. Res. 876), H252 [19JA]

——— improve requirements for making determination of interchangeability of biological product and its reference product (see S. 6), S6778 [17NO]

——— modernize methods of authenticating controlled substances in pharmaceutical distribution supply chain (see H.R. 7653), H4713 [3MY]

——— modernize therapeutic equivalence rating determinations (see H.R. 7377), H4152 [4AP]

——— preserve access to abortion medications (see S. 4467), S3159 [23JN] (see H.R. 8405), H6706 [18JY]

——— prevent food shortages, including shortages of infant formula and certain medical foods (see S. 4256), S2586 [18MY] (see H.R. 7989), H5409 [8JN]

——— prohibit alteration, falsification, fabrication, destruction, omission, or removal of records or certain information required to be produced or maintained for drugs (see H.R. 6431), H252 [19JA]

——— promulgate rule relative to disclosure of side effects, contraindications, and effectiveness in prescription drug ads while also prohibiting distracting representations that detract from such disclosures (see H.R. 8289), H5935 [5JY]

——— protect access to kratom (see S. 5316), S9625 [20DE] (see H.R. 9634), H9909 [20DE]

——— provide for mandatory recall authority over regulated drugs and homeopathic products (see H.R. 6834), H1146 [25FE]

——— provide for period of exclusivity for first interchangeable biological products (see S. 4303), S2708 [25MY]

——— provide increased transparency in generic drug applications (see S. 4338), S2752 [26MY]

——— provide process to lock and suspend domain names used to facilitate online sale of drugs illegally (see S. 3984), S1910 [31MR]

——— publicly release summary of reasoning for approving drugs, biological products, and other therapies via accelerated approval process (see S. 4390), S2939 [14JN]

——— reauthorize Critical Path Public-Private Partnerships (see S. 4152), S2358 [5MY] (see H.R. 7658), H4713 [3MY]

——— repeal authority to require that drugs be dispensed only upon prescription (see H.R. 6512), H307 [28JA]

——— report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices (see H.R. 6710), H1119 [11FE]

——— require foreign establishments engaged in production of drug or device to register whether or not drug or device undergoes further processing at separate location outside U.S. prior to being imported (see S. 3449), S117 [10JA]

——— require guidance on extending expiration dates for certain scarce drugs (see S. 3493), S189 [12JA] (see H.R. 7669), H4721 [6MY]

——— require manufacturers to report medical device shortages, expedite review of essential medical devices, and grant authority to request information relative to security of U.S. medical product supply chain (see H.R. 7208), H3862 [24MR]

——— require more accurate reporting of abortion drug prescribing and related adverse events (see H.R. 6702), H1114 [9FE]

——— require prompt reports on marketing status by holders of approved applications for biological products (see S. 4302), S2708 [25MY] (see H.R. 7035), H1422 [9MR]

——— revise and extend user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products (see S. 4348), S2752 [26MY] (see S. 4535), S3308 [14JY] (see H.R. 7667), H4721 [6MY]

——— set forth limitations on exclusivity for orphan drugs (see S. 4185), S2449 [11MY]

——— shorten exclusivity period for brand name biological products (see H.R. 7828), H5174 [18MY]

——— strengthen authority relative to foreign drug facility inspections (see S. 3509), S220 [13JA]

——— strengthen requirements for postapproval studies for drugs approved using accelerated approval (see H.R. 6963), H1329 [7MR]

——— strengthen review and approval of drugs to treat rare diseases and conditions (see S. 4071), S2092 [7AP] (see H.R. 6888), H1207 [1MR]

Federal Food, Drug, and Cosmetic Act: reauthorize provision relative to drugs containing single enantinomers (see S. 4378), S2910 [13JN]

FTC: prevent unfair and deceptive acts or practices and dissemination of false information relative to pharmacy benefit management services for prescription drugs (see S. 4293), S2664 [24MY]

GAO: conduct study relative to coronavirus immunity resulting from prior infection, vaccination, or both (see S. 3809), S1118 [10MR]

——— issue report on nonprofit pharmaceutical organizations (see S. 4341), S2752 [26MY]

Government: prohibit from compiling or maintaining list of Federal employees who requested or been granted religious exemption to coronavirus vaccination requirement (see H.R. 7036), H1422 [9MR]

Greene, Representative: condemn and censure (see H. Res. 1410), H8316 [29SE]

Health: address high cost of health care services, prescription drugs, and health insurance coverage (see H.R. 8588), H7405 [28JY]

——— prohibit consideration of race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, political ideology, or speech in determining eligibility for monoclonal antibody doses (see S. 3974), S1910 [31MR]

——— provide for designation of biological products as qualified infectious disease products (see S. 3478), S159 [11JA]

——— provide for national uniformity for reproductive health products (see S. 4748), S3862 [2AU]

——— require certain drug manufacturers entering into settlement agreements for violations of law to make supplemental payments to increase medical research funding (see S. 5322), S9625 [20DE] (see H.R. 9687), H10055 [22DE]

——— review and improve domestic biopharmaceutical manufacturing capabilities and public health and medical preparedness and response (see S. 3553), S496 [2FE]

Inflation Reduction Act: repeal Medicare prescription drug price control provisions (see S. 4953), S5051 [27SE]

Insurance: allow membership organizations to offer health insurance to members through health share pools, including across State lines, regardless of employment relationship or pre-existing condition (see S. 5303), S9625 [20DE]

——— clarify Federal Right To Try laws apply to schedule 1 substances for which phase 1 clinical trial has been completed and provide access to eligible patients to such substances (see S. 4575), S3542 [20JY] (see H.R. 8440), H6921 [20JY]

——— establish new coverage and payment rules for certain coronavirus diagnostic tests and related items and service (see H.R. 6851), H1146 [25FE]

——— require group health plans and group or individual health insurance coverage to provide coverage for over-the-counter contraceptives (see S. 4347), S2752 [26MY] (see H.R. 7894), H5219 [27MY]

——— require health insurance providers to issue notices relative to prescription drug refills to individuals residing in emergency areas during emergency periods (see H.R. 8270), H5929 [1JY]

——— require out-of-network coverage for qualified individuals participating in approved clinical trials (see H.R. 8546), H7255 [27JY]

Medicaid: codify value-based purchasing arrangements and reforms relative to price reporting under such arrangements (see H.R. 7389), H4152 [4AP]

——— require coverage for annual lung cancer screening with no cost sharing for certain individuals and expand coverage of counseling and pharmacotherapy for cessation of tobacco use (see H.R. 9336), H8587 [17NO]

Medical devices: strengthen medical device supply chains (see S. 3834), S1153 [14MR]

Medicare: direct Sec. of HHS to provide documentation to House of Representatives relative to negotiation of prices for prescription drugs under prescription drug program (see H. Res. 1284), H7170 [26JY]

——— ensure Medicare-only PACE program enrollees have choice of prescription drug plans under part D (see S. 5106), S6740 [16NO]

——— establish cap on costs for covered prescription drugs (see S. 3615), S612 [9FE]

——— establish Medicare for America program to provide comprehensive health insurance coverage for all U.S. citizens (see H.R. 9655), H9983 [21DE]

——— establish minimum amount of price concessions for insulin to be passed through to beneficiaries at point-of-sale (see H.R. 6757), H1129 [18FE]

——— exclude independent agents and brokers from requirement to record calls with beneficiaries under Medicare Advantage and prescription drug benefit programs (see S. 5149), S6905 [30NO]

——— improve access to opioid use disorder treatment services (see S. 4618), S3694 [26JY]

——— make premium and cost-sharing subsidies available to low-income part D beneficiaries residing in Puerto Rico or other U.S. territories (see S. 3778), S1059 [8MR]

——— promote access to opioid treatments and require coverage of medication assisted treatment, overdose reversal medications, and recovery support services by health plans without cost-sharing requirements (see S. 5008), S5540 [29SE]

——— protect part D six protected classes (see H. Res. 1390), H8113 [22SE]

——— provide for cap on beneficiary liability under part D (see S. 4011), S2040 [6AP]

——— provide outreach and reporting on opioid use disorder treatment services furnished by opioid treatment programs (see H.R. 8884), H7964 [19SE]

——— provide pharmacy reimbursement for coronavirus-related and future emergency services (see H.R. 7213), H3863 [24MR]

——— provide review process for adverse national coverage determinations relative to drug coverage of certain new, innovative treatments (see H.R. 9358), H8647 [29NO]

Medicare/Medicaid: prohibit any conditions of participation that include vaccine or drug mandate (see H.R. 6414), H216 [18JA]

——— provide coverage of prescription digital therapeutics for treatment of mental health and substance use disorders (see S. 3791), S1118 [10MR] (see H.R. 7051), H1423 [9MR]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (see H.R. 7529), H4443 [14AP]

National Academies of Sciences, Engineering, and Medicine: conduct study relative to coronavirus immunity resulting from prior infection, vaccination, or both (see S. 3831), S1153 [14MR]

National Adult Hepatitis B Vaccination Awareness Day: designate (see S. Res. 602), S2219 [28AP] (see H. Res. 1072), H4608 [28AP]

National Fentanyl Awareness Day: designate (see S. Res. 624), S2381 [9MY] (see H. Res. 1102), H4797 [10MY]

National Guard: prohibit any requirement that members receive vaccination against coronavirus (see S. 4499), S3200 [11JY]

NIH: establish Advanced Research Projects Authority for Health (see S. 3819), S1119 [10MR]

——— establish or continue research program to advance discovery and preclinical development of medical products for priority virus families and other viral pathogens with significant pandemic potential (see S. 3489), S189 [12JA]

——— take certain steps to increase clinical trial diversity (see S. 5268), S7252 [15DE] (see H.R. 7845), H5207 [19MY]

Older Americans Mental Health Awareness Day: designate (see S. Res. 657), S2752 [26MY]

OSHA: clarify scope of authority for emergency temporary standards relative to mandatory coronavirus vaccination or testing (see S. 3555), S496 [2FE]

——— prohibit enforcement of any drug or vaccine mandates (see H.R. 7127), H3826 [17MR]

——— provide that rule relative to mandatory vaccine mandates for certain businesses shall have no force or effect (see S. 3461), S118 [10JA]

Patent and Trademark Office: improve process to challenge validity of patents through Patent Trial and Appeal Board (see S. 4417), S3003 [16JN]

Patient Protection and Affordable Care Act: ensure tax payer funds for health insurance coverage are available only to authorized individuals (see H.R. 8441), H6921 [20JY]

Political ethics: prohibit former employees of certain health agencies from serving on board of entities involved in development and research of covered vaccines (see H.R. 9708), H10550 [3JA]

Postal Service: provide authority for small cultivators of marijuana and small manufacturers of marijuana products to ship marijuana and marijuana products using the mail (see H.R. 8825), H7841 [14SE]

Rare Disease Day: designate (see H. Res. 948, 952), H1176 [28FE]

Research: increase transparency of costs (see S. 4037), S2091 [7AP] (see H.R. 7474), H4432 [7AP]

Schools: prohibit provision of Federal funds to local educational agencies that impose or enforce coronavirus vaccine mandate on students at schools served by such agencies (see H.R. 9280), H8433 [7NO]

Senate: prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (see S. Res. 631), S2493 [12MY]

Social Security: clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes (see H.R. 9378), H8707 [1DE]

Substance Abuse and Mental Health Services Administration: extend residential treatment program for pregnant and postpartum women pilot program (see S. 5285), S7252 [15DE]

——— study certain exemptions for treatment of opioid use disorder through treatment programs during coronavirus emergency and modernize process for obtaining methadone (see S. 3629), S647 [10FE]

Tardive Dyskinesia Awareness Week: designate (see H. Res. 1107), H4861 [11MY]

Taxation: prohibit deduction for prescription drug advertising and promotional expenses (see H.R. 6392), H193 [13JA]

——— provide extended expensing of pharmaceutical manufacturing property and production tax credit for pharmaceuticals and active pharmaceutical ingredients (see H.R. 7166), H3853 [18MR]

——— provide tax credit for domestic medical and drug manufacturing and advanced medical manufacturing equipment (see H.R. 7410), H4191 [5AP]

——— raise health savings accounts contributions limit, remove requirement to maintain high deductible coverage relative to such accounts, and include drugs as qualified medical expenses (see H.R. 6474), H294 [21JA]

Trucking industry: exempt commercial truck drivers from Canada or Mexico seeking to temporarily enter U.S. for business through land port of entry from any coronavirus vaccination requirement (see S. 3701), S786 [17FE] (see H.R. 6809), H1139 [22FE]

21st Century Cures Act: amend State Opioid Response Grants program (see H.R. 7189), H3858 [21MR]

U.N. Commission on Narcotic Drugs: encourage U.S. representative to use voice, vote, and influence of U.S. to deschedule cannabis from Schedule I of Single Convention of Narcotic Drugs (see H. Con. Res. 81), H3858 [21MR]

U.S. service academies: prohibit denial of graduation, dismissal, or assessment of repayment claims for cadets and midshipmen who refuse to get coronavirus vaccine (see S. 4304), S2708 [25MY] (see H.R. 7890), H5219 [27MY]

Vaccines: hold vaccine manufacturers liable for injuries caused by vaccines subject to public mandate (see H.R. 9366), H8673 [30NO]

van Hoek, Jan: relief (see H.R. 9694), H10531 [23DE]

Veterans: ensure servicemembers granted general discharge under honorable conditions on sole basis of failure to obey lawful order to receive coronavirus vaccine is eligible for certain educational assistance (see H.R. 6671), H1112 [9FE]

Cloture motions

Drugs: establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), S5148 [28SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), motion to proceed, S4955 [22SE], S5045 [27SE]

Cost Estimates

Inflation Reduction Act (H.R. 5376): CBO, H7662 [12AU]

Prevent Exposure to Narcotics and Toxics (PREVENT) Act (H.R. 5274): CBO, E667 [23JN]

Emails

Require insurance companies to reimburse providers for administration of coronavirus vaccines: John M. Prible, UnitedHealthcare, Inc., S379 [20JA]

Essays

State of the Union: Samantha Haselman, S1152 [14MR]

Letters

Affordable Insulin Now Act: Bob Carlstrom, AMAC Action (organization), H4039 [31MR]

——— James P. Gelfand, ERISA Industry Committee (organization), H4040 [31MR]

——— Kevin Kuhlman, National Federation of Independent Business, H4039 [31MR]

——— Partnership for Employer-Sponsored Coverage (organization), H4039 [31MR]

——— Tom Schatz, Council for Citizens Against Government Waste, H4039 [31MR]

Ensure equitable treatment of covered entities and pharmacies participating in 340B drug discount program: several Representatives, H5325 [7JN]

Inflation Reduction Act: several economists, H7697 [12AU]

Inflation Reduction Act drug price control policies: House of Representatives GOP Doctors Caucus, H7682 [12AU]

Inflation Reduction Act prescription drug reforms: Dan Leonard, Association of Accessible Medicines Biosimilars Council, H7677 [12AU]

Inflation Reduction Act provisions impact on launch prices of new drugs and introduction of new generic drugs: Phillip L. Swagel, CBO, H7649, H7665 [12AU]

Medical Marijuana Research Act: Representative Nadler, Committee on the Judiciary (House), E371 [7AP]

——— Representative Pallone, Committee on Energy and Commerce (House), E371 [7AP]

Prevent Exposure to Narcotics and Toxics (PREVENT) Act: Representative Bennie G. Thompson, Committee on Homeland Security (House), H5694 [21JN]

——— Representative Neal, Committee on Ways and Means (House), H5694 [21JN]

Require insurance companies to reimburse providers for administration of coronavirus vaccines: Brian Thompson, UnitedHealthcare, Inc., S378 [20JA]

——— Senator Casey, Committee on Aging (Senate, Special), S377 [20JA]

Revise and extend FDA user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products: Xavier Becerra, Sec. of HHS, S5171, S5172, S5173, S5174, S5175, S5176, S5177 [28SE]

Lists

Committee on Taxation (Joint) staff working on H.R. 5376, Inflation Reduction Act, S4954 [22SE]

Congressional Budget Office staff working on H.R. 5376, Inflation Reduction Act, S4954 [22SE]

Organizations opposing H.R. 5376, Inflation Reduction Act, H7678 [12AU]

Votes recorded by proxy on Bucshon motion to recommit H.R. 6833, Affordable Insulin Now Act, H4054 [31MR]

Votes recorded by proxy on Eshoo amendment to H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act, H5808 [22JN]

Votes recorded by proxy on H. Res. 973, consideration of H.R. 7007, supplemental appropriations for coronavirus emergency response and relief, H1394 [9MR]

Votes recorded by proxy on H. Res. 1017, consideration of H.R. 6833, Affordable Insulin Now Act, H4033 [31MR]

Votes recorded by proxy on H. Res. 1191, consideration of H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act, H5752 [22JN]

Votes recorded by proxy on H. Res. 1316, consideration of Senate amendment to H.R. 5376, Inflation Reduction Act, H7577 [12AU]

Votes recorded by proxy on H.R. 5274, Prevent Exposure to Narcotics and Toxics (PREVENT) Act, H6287 [13JY]

Votes recorded by proxy on H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act, H5809 [22JN]

Votes recorded by proxy on H.R. 5657, Medical Marijuana Research Act, H4144 [4AP]

Votes recorded by proxy on H.R. 6833, Affordable Insulin Now Act, H4055 [31MR]

Votes recorded by proxy on H.R. 7667, revise and extend FDA user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, H5403 [8JN]

Votes recorded by proxy on H.R. 8454, Medical Marijuana and Cannabidiol Research Expansion Act, H7146 [26JY]

Votes recorded by proxy on Latta motion to recommit H.R. 3617, Marijuana Opportunity Reinvestment and Expungement (MORE) Act, H4115 [1AP]

Votes recorded by proxy on previous question to H. Res. 973, consideration of H.R. 7007, supplemental appropriations for coronavirus emergency response and relief, H1393 [9MR]

Votes recorded by proxy on previous question to H. Res. 1017, consideration of H.R. 6833, Affordable Insulin Now Act, H4032 [31MR]

Votes recorded by proxy on previous question to H. Res. 1191, consideration of H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act, H5751 [22JN]

Votes recorded by proxy on previous question to H. Res. 1316, consideration of Senate amendment to H.R. 5376, Inflation Reduction Act, H7575 [12AU]

Votes recorded by proxy on S. 2796, Rural Area Opioid Prevention Act, H8778 [6DE]

Votes recorded by proxy on Senate amendment to H.R. 5376, Inflation Reduction Act, H7704 [12AU]

Messages

National Emergency Relative to Global Illicit Drug Trade: President Biden, S7099 [12DE]

Motions

Centers for Medicare & Medicaid Services: disapprove rule entitled ‘‘Medicare and Medicaid Programs; Omnibus COVID–19 Health Care Staff Vaccination’’ (S.J. Res. 32), S874 [1MR]

Drugs: establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), S4955 [22SE], S5037 [27SE], S5148 [28SE], H4046 [31MR], H8346 [30SE]

Notices

Estimated budget effects of H.R. 5657, Medical Marijuana Research Act, H4152 [4AP]

Estimated budget effects of H.R. 7667, revise and extend FDA user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, H5330 [7JN]

Estimated budget effects of H.R. 8454, Medical Marijuana and Cannabidiol Research Expansion Act, H7163 [26JY]

Papers

Evidence Base on the Impact of Price Controls on Medical Innovation: Tomas J. Philipson and Troy Durie, University of Chicago, H7671–H7673 [12AU]

Press releases

Nonpartisan Tax Scorekeeper—Average Working Family Is More Likely To Be Worse Off Than Better Off Under Democrat’s Tax Plan: Committee on Ways and Means (House) Republican Staff, H7663 [12AU]

U.S. Overdose Deaths in 2021 Increased Half as Much as in 2020—But Are Still Up 15 Percent: CDC, H8747 [5DE]

Remarks in House

Abortion: prohibit award of Federal funds to higher education institutions that host or are affiliated with student-based service site that provides abortion drugs or abortions to students or employees (H.R. 4607), H227 [19JA]

All American Pharmaceutical (company): development of new baby formula in response to infant formula shortage, E731 [14JY]

Armed Forces: prohibit any requirement that members be vaccinated against coronavirus (H.R. 3860), H8782 [6DE]

——— prohibit denial of any Federal education benefit to which members are entitled solely on basis of refusal to receive coronavirus vaccine, H57 [12JA]

——— reinstate servicemembers involuntarily separated solely due to refusal to receive vaccination against coronavirus, H8058, H8059 [21SE]

——— reinstate servicemembers who failed to obey order to receive coronavirus vaccine, H5981 [13JY]

Bedford, PA: anniversary of Letrent’s Pharmacy, E158 [18FE]

Biden, President: evaluation of administration relative to coronavirus pandemic, H190 [13JA], H227 [19JA], H1337 [8MR], H3847 [18MR], H8015 [21SE], H8322 [30SE]

——— evaluation of administration relative to economy, H7413 [29JY]

——— State of the Union Message, H1213, H1258 [2MR], H1277 [3MR]

Business and industry: address market consolidation in pharmaceutical industry, H1214 [2MR]

California: tribute to 36th Congressional District pharmacies and health centers for efforts to distribute coronavirus vaccines to underserved communities, E390 [18AP]

CDC: conduct public education campaign that raises public awareness of dangers of synthetic opioids and explains services available relative to opioid treatment, H5791 [22JN]

Centers for Medicare & Medicaid Services: decision to restrict coverage of Biogen, Inc., Alzheimer’s disease drug, H4577 [28AP]

——— implement drug manufacturer discount program, H7702 [12AU]

Committee on Energy and Commerce (House): tribute to staff working on H.R. 5376, Inflation Reduction Act, H7690 [12AU]

Courts: assessment of liability protections available to individuals and entitities in pharmaceutical, social media, and political industries, H6947 [21JY]

Daytona Beach, FL: opening of B. Braun Medical, Inc., pharmaceutical manufacturing plant, E942 [15SE]

DEA: clarify process for registrants to exercise due diligence upon discovering suspicious orders, H5791 [22JN]

——— make permanent scheduling of fentanyl-related substances (H.R. 6184), H352, H353, H901, H902, H903 [2FE], H979, H982 [7FE], H1021, H1062 [8FE], H4094 [1AP], H8083 [22SE], H8174–H8177 [28SE]

——— provide for life imprisonment for certain offenses involving fentanyl (H.R. 6439), H901 [2FE], H1063 [8FE]

Democratic Party: national agenda, H7238 [27JY]

Dept. of Defense: coronavirus vaccine mandate, H8821 [7DE]

——— establish grant program to study use of psychedelic treatments for veterans and servicemembers with post-traumatic stress disorder, H6264 [13JY]

——— require bi-monthly report on number of religious and medical exemptions for coronavirus vaccine mandate, H6263 [13JY]

Dept. of HHS: allow women greater access to safe and effective oral contraceptive drugs intended for routine use, H6938 [21JY]

——— anniversary of 340B Drug Pricing Program, H1024 [8FE], H5325–H5330 [7JN], H5451 [13JN], E595 [8JN], E608 [9JN]

——— authorize grants to develop strategic response plans relative to opioid crisis and require providers prescribing opioids for certain patients to also prescribe opioid overdose reversal drugs (H.R. 5224), H1324 [7MR], H9850 [14DE]

——— enter agreement with National Academies of Sciences, Engineering, and Medicine to conduct study on quality and effectiveness of covered recovery housing in the U.S., H5781 [22JN]

——— establish Advanced Research Projects Agency-Health, H1413 [9MR]

——— establish Advanced Research Projects Agency-Health (H.R. 5585), H5633 [16JN], H5795–H5803 [22JN], H5834 [23JN]

——— establish Advanced Research Projects Agency-Health (H.R. 5585), consideration (H. Res. 1191), H5745–H5752 [22JN], E659 [23JN]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H188 [13JA], H248 [19JA], H1068 [8FE], H4044, H4060 [31MR]

——— establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids (H.R. 2366), H39 [11JA], H1157 [28FE]

——— improve inspections of foreign drug manufacturing establishments, E594 [8JN]

——— reauthorize and expand State Opioid Response Grants program, H5791 [22JN]

——— reauthorize grant program for screening, assessment, and treatment services for maternal mental health and substance use disorders, H5747, H5779 [22JN]

——— require Inspector General investigation and report on Vaccine Adverse Event Reporting System (H.R. 7308), H4158 [5AP]

——— revise opioid treatment program admission criteria to eliminate requirement that patients have been addicted for at least 1 year prior to being admitted for treatment, H5779 [22JN]

Dept. of Homeland Security: provide training for U.S. Customs and Border Protection personnel on use of containment devices to prevent secondary exposure to fentanyl and other potentially lethal substances (H.R. 5274), H5693–H5695 [21JN], E656 [22JN]

Dept. of Justice: provide for eligibility of rural community response pilot programs for funding under Comprehensive Opioid Abuse Grant Program (S. 2796), H8745–H8750 [5DE]

Dept. of Veterans Affairs: ensure certain medical facilities have physical locations for disposal of controlled substances or medications (H.R. 2591), H904 [2FE]

Diseases and disorders: global coronavirus vaccine access funding, H4563 [27AP]

——— making supplemental appropriations for coronavirus emergency response and relief, H4158 [5AP]

——— making supplemental appropriations for coronavirus emergency response and relief (H.R. 7007), consideration (H. Res. 973), H1390–H1394 [9MR]

——— prohibit funding for coronavirus vaccine mandate, H971–H973 [4FE]

——— prohibit use of Federal funds to implement or enforce coronavirus vaccine mandates, H4520 [27AP], H8053 [21SE], H8110 [22SE]

——— prohibit vaccination mandates for coronavirus, H343 [2FE]

——— raise awareness about cancer chordoma (H. Res. 1514), H9706 [13DE]

——— use of budget reconciliation to provide emergency assistance and health care response for individuals, families, and businesses affected by coronavirus pandemic (H.R. 1319), E1302 [15DE]

——— use of certain drugs against coronavirus, H210 [18JA], H250 [19JA], H998 [7FE], H1091 [9FE], H3847 [18MR]

Drug abuse: designate methamphetamine as emerging threat (S. 854), H1156–H1158 [28FE]

Drugs: address drug abuse epidemic by securing southern border, H921, H922 [3FE], H979 [7FE], H1061, H1062–H1067 [8FE], H4059 [31MR], H4461 [26AP], H4583 [28AP], H4848 [11MY], H4869 [12MY], H6925 [21JY], H7080 [26JY], H8746 [5DE]

——— address drug overdose deaths, H6879 [19JY]

——— address prescription opioid abuse, H5102 [18MY], H8705 [1DE]

——— ensure equitable treatment of covered entities and pharmacies participating in 340B drug discount program (H.R. 4390), H5325–H5330 [7JN], H5451 [13JN]

——— establish cap on out-of-pocket costs for insulin, H3819 [17MR]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), H3982, H4003 [30MR], H4022, H4033–H4046, H4053–H4057 [31MR], H4077 [1AP], H4130, H4147, H4148 [4AP], H4199, H4200, H4203 [6AP], H7076 [26JY], E362 [6AP]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), consideration (H. Res. 1017), H4023–H4033 [31MR]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), consideration of Senate amendment (H. Res. 1404), H8323–H8330 [30SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), correction in enrollment (S. Con. Res. 45), H8354 [30SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), Senate amendment, H8104 [22SE], H8226 [29SE], H8330–H8350 [30SE]

——— facilitate responsible, informed dispensing of controlled substances and other prescribed medications, H5778, H5791 [22JN]

——— improve medical research on marijuana by simplifying registration process to conduct research, facilitating access for such research, and allowing private manufacture and distribution for research purposes (H.R. 5657), H4136–H4140 [4AP]

——— increase number of days before which certain controlled substances for maintenance or detoxification treatment must be administered, H5791 [22JN], H5835 [23JN]

——— reduce threshold for mandatory minimum penalties for certain fentanyl-related offenses (H.R. 5694), H1064 [8FE]

Economy: use of budget reconciliation to fight inflation, reduce prescription drug and health care costs, address climate change, increase tax fairness, and reduce deficit, H6943 [21JY]

——— use of budget reconciliation to make visionary and transformative investments in health, well-being, and financial security of America’s workers and families, H1298 [3MR]

——— use of budget reconciliation to make visionary and transformative investments in health, well-being, and financial security of America’s workers and families (H.R. 5376), H20 [11JA], H176, H177, H181, H191 [13JA], H249, H251 [19JA], H4570 [27AP]

Eli Lilly and Co.: tribute to shipments of medicine to Ukraine and surrounding areas following Russian invasion, H4812 [11MY]

FDA: clarify reporting requirements for establishments within foreign country engaged in manufacture, preparation, propagation, compounding, or processing of active pharmaceutical ingredients, H827 [2FE]

——— enhance data reporting on clinical trial demographics and provide resources to improve access to clinical trials in underrepresented communities, E594 [8JN]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (H.R. 554), H281 [20JA]

——— revise and extend user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products (H.R. 7667), H5298–H5321 [7JN], E594, E599 [8JN], E629 [15JN]

Foundation for the National Institutes of Health: increase funding (S. 1662), H1159 [28FE]

Health: discourage vaccine requirements, H8308 [29SE]

——— ensure physicians and health care providers advise patients of potential risk of coronavirus vaccine and hold health care providers and pharmaceutical companies liable for any damages, H8110 [22SE]

——— transfer pharmaceutical civil penalties to NIH Gabriella Miller Kids First Pediatric Research Program Fund (H.R. 623), H7124–H7126 [26JY], H7197, H7223 [27JY]

Horsham, PA: tribute to PMC Pharmacy (business) employees for efforts to combat prescription opioid addiction epidemic while serving needs of chronic pain patients, E700 [7JY]

Inflation Reduction Act: impact, H7745, H7746 [13SE], H7788, H7795 [14SE], H7846, H7847, H7848, H7863–H7868 [15SE], H7947, H7948, H7950, H7959, H7960 [19SE], H7974, H7981 [20SE], H8123 [28SE], H8228, H8298 [29SE]

Insurance: clarify Federal Right To Try laws apply to schedule 1 substances for which phase 1 clinical trial has been completed and provide access to eligible patients to such substances (H.R. 8440), E757 [20JY]

——— require Pharmacy Benefit Managers to provide greater transparency to group health plan participants, H5780 [22JN]

Jamaica: U.S. policy, E333 [31MR]

Medicaid: require coverage for annual lung cancer screening with no cost sharing for certain individuals and expand coverage of counseling and pharmacotherapy for cessation of tobacco use (H.R. 9336), H8677 [1DE]

Medicare: part B premium increase relative to projected cost of Alzheimer’s drug, H238 [19JA]

Medicare/Medicaid: lower prescription drug prices, H4518 [27AP]

National objectives: improve health care services, H6869–H6875 [19JY], H8819–H8821 [7DE], H8863–H8865 [8DE]

National Pharmacist Day: observance, H74 [12JA]

Rare Disease Day: designate (H. Res. 948), E185 [28FE]

——— designate (H. Res. 952), E181, E190 [28FE]

Substance Abuse and Mental Health Services Administration: study certain exemptions for treatment of opioid use disorder through treatment programs during coronavirus emergency and modernize process for obtaining methadone (H.R. 6279), E1211 [2DE]

Supreme Court: decision in National Federation of Independent Business v. Dept. of Labor relative to OSHA rule regarding vaccine mandates for certain businesses, H176 [13JA]

Utah: tribute to companies for innovation in health care industry, H8128 [28SE], E961 [21SE]

Remarks in Senate

Armed Forces: preserve readiness by limiting separations based on coronavirus vaccination status and continuing pay and benefits for members while religious and health accommodations are pending, S6641 [14NO]

Biden, President: evaluation of administration, S631 [10FE]

——— evaluation of administration relative to coronavirus pandemic, S15–S17, S20 [4JA], S33, S38–S40, S44 [5JA], S469, S482 [2FE], S532 [7FE]

——— State of the Union Message, S922 [2MR], S969 [3MR]

Centers for Medicare & Medicaid Services: disapprove rule entitled ‘‘Medicare and Medicaid Programs; Omnibus COVID–19 Health Care Staff Vaccination’’ (S.J. Res. 32), S924, S933–S936 [2MR], S963 [3MR]

Children and youth: address shortage of pediatric medication, S7812 [20DE]

Committee on Health, Education, Labor, and Pensions (Senate): accomplishments, S9716–S9718 [21DE]

Congress: accomplishments of 117th Congress, S9 [4JA], S7044 [8DE]

Controlled Substances Act: amend to fix technical error in definitions (S. 4235), S4624 [14SE]

Coronavirus Aid, Relief, and Economic Security (CARES) Act: anniversary, S1284–S1286 [22MR]

Democratic Party: national agenda, S3286 [14JY]

Dept. of Defense: coronavirus vaccine mandate, S6815 [28NO]

Dept. of HHS: allow women greater access to safe and effective oral contraceptive drugs intended for routine use (S. 4638), S3726 [27JY]

——— allow women greater access to safe and effective oral contraceptive drugs intended for routine use (S. 4638), unanimous-consent request, S3726, S3727 [27JY]

——— disapprove rule entitled ‘‘Vaccine and Mask Requirements To Mitigate the Spread of COVID–19 in Head Start Programs’’ (S.J. Res. 39), S2265 [3MY], S2294 [4MY]

——— disapprove rule entitled ‘‘Vaccine and Mask Requirements To Mitigate the Spread of COVID–19 in Head Start Programs’’ (S.J. Res. 39), unanimous-consent agreement, S2259 [3MY]

——— provide for appropriate cost-sharing for insulin products covered under Medicare part D and private health plans (S. 3700), S2345 [5MY]

——— State Opioid Response Grants program funding, S1111, S1112 [10MR]

Diseases and disorders: continue to assist countries in vaccinating against coronavirus, S2004 [6AP]

——— making supplemental appropriations for coronavirus emergency response and relief, S961 [3MR], S1006 [7MR], S1024 [8MR], S1070, S1073 [10MR], S1793 [28MR], S1812 [29MR], S1843–S1845, S1849 [30MR], S1876, S1886 [31MR], S1922 [4AP], S1949, S1964, S1965 [5AP], S1992, S2024 [6AP], S2118, S2119 [25AP], S2136 [26AP], S2174 [27AP], S2202 [28AP], S2235 [2MY], S2467 [12MY], S2514 [16MY], S2603 [19MY]

——— prepare for, and respond to, existing viruses, emerging new threats, and pandemics (S. 3799), S7060 [8DE]

——— prohibit use of Federal funds to implement or enforce coronavirus vaccine mandates, S775–S777 [17FE], S1106–S1108 [10MR]

Drugs: address drug abuse epidemic by securing southern border, S2175 [27AP], S2530 [17MY], S4951 [22SE]

——— address prescription opioid and heroin abuse, S657 [14FE]

——— establish cap on out-of-pocket costs for insulin, S1719 [23MR]

——— establish requirements relative to cost-sharing for certain insulin products, S3046 [22JN], S4193 [6AU]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), S2668, S2669 [24MY], S5147 [28SE], S5509, S5511, S5519, S5520 [29SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), correction in enrollment (S. Con. Res. 45), S5521 [29SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), motion to proceed, S4955 [22SE], S5037, S5041, S5042, S5045 [27SE], S5115–S5117, S5120, S5147 [28SE]

——— establish requirements relative to cost-sharing for certain insulin products (H.R. 6833), unanimous-consent agreement, S5515 [29SE]

——— lower prescription drug costs for consumers, S3303 [14JY]

——— modernize process of accelerated approval of drugs for serious or life-threatening diseases or conditions (S. 4446), S3077 [22JN]

——— prohibit deceptive sale of fentanyl (S. 4984), S5130, S5131 [28SE]

——— prohibit deceptive sale of fentanyl (S. 4984), unanimous-consent request, S5130, S5131 [28SE]

——— provide funding to federally-qualified health centers to offer insulin or injectable epinephrine at discounted prices, S4193 [6AU]

Economy: use of budget reconciliation to fight inflation, reduce prescription drug and health care costs, address climate change, increase tax fairness, and reduce deficit, S3194 [11JY]

——— use of budget reconciliation to fight inflation, reduce prescription drug and health care costs, address climate change, increase tax fairness, and reduce deficit (H.R. 5376), S3729 [27JY], S3749–S3752, S3766–S3768, S3772 [28JY], S3794, S3795, S3797 [1AU], S3837, S3839, S3842, S3853–S3856, S3857, S3858, S3869–S3871 [2AU], S3873, S3874–S3877, S3901, S3994–S3998 [3AU], S4004–S4009, S4015–S4017, S4023, S4026–S4031 [4AU], S4051–S4201, S4210–S4212 [6AU], S4434 [6SE], S4461, S4462 [7SE], S4506 [8SE], S5171 [28SE]

——— use of budget reconciliation to make visionary and transformative investments in health, well-being, and financial security of America’s workers and families (H.R. 5376), S6, S9 [4JA], S470 [2FE], S2141 [26AP], S2348 [5MY]

FDA: allow for alternatives to animal testing for purposes of drug and biological product applications (S. 5002), S5514 [29SE]

——— provide for period of exclusivity for first interchangeable biological products (S. 4303), S2709 [25MY]

——— reform procedures relative to approval of opioid drugs, S685 [15FE]

——— require guidance on extending expiration dates for certain scarce drugs (S. 3493), S191 [12JA]

——— require prompt reports on marketing status by holders of approved applications for biological products (S. 4302), S2709 [25MY]

——— revise and extend user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, S5171 [28SE]

——— revise and extend user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products (H.R. 7667), S4630 [15SE]

Federal agencies and departments: prohibit from promulgating rules requiring proof of coronavirus vaccination to engage in interstate commerce or travel (S. 2895), S38–S40 [5JA]

——— prohibit from promulgating rules requiring proof of coronavirus vaccination to engage in interstate commerce or travel (S. 2895), unanimous-consent request, S39 [5JA]

FTC: prevent unfair and deceptive acts or practices and dissemination of false information relative to pharmacy benefit management services for prescription drugs (S. 4293), S3021 [21JN], S5133 [28SE]

Health: address high cost of health care services, prescription drugs, and health insurance coverage, S4553–S4556 [13SE]

——— increase domestic pharmaceutical manufacturing capabilities, S7812 [20DE]

——— urge unvaccinated people to get coronavirus vaccine, S3840 [2AU]

Health care professionals: require insurance companies to reimburse providers for administration of coronavirus vaccines, S375 [20JA]

Health Wagon, Inc.: anniversary, S2812 [7JN]

Inflation Reduction Act: impact, S4420, S4423 [6SE], S4452 [7SE], S4953 [22SE], S5038 [27SE]

Medicare: establish cap on costs for covered prescription drugs, S4145–S4147, S4170 [6AU]

——— establish cap on costs for covered prescription drugs (S. 3615), S604–S607 [9FE]

——— establish cap on costs for covered prescription drugs (S. 3615), unanimous-consent request, S604, S607 [9FE]

——— exclude certain categories of drugs from price controls for covered prescription drugs, S4181 [6AU]

——— improve access to opioid use disorder treatment services (S. 4618), S3696 [26JY]

Medicare/Medicaid: lower prescription drug prices, S5133 [28SE]

——— lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers, S429 [1FE], S1039 [8MR], S1883 [31MR], S3189 [11JY], S3321, S3324 [18JY], S3346 [19JY], S3505, S3509, S3520 [20JY], S3582 [21JY], S3620, S3621 [25JY], S3669 [26JY], S3716 [27JY], S4065, S4167 [6AU]

National Fentanyl Awareness Day: designate (S. Res. 624), S2384 [9MY]

Older Americans Mental Health Awareness Day: designate (S. Res. 657), S2737 [26MY]

OSHA: disapprove rule relative to mandatory vaccine mandates for certain businesses (S.J. Res. 29), S38 [5JA]

——— provide that rule relative to mandatory vaccine mandates for certain businesses shall have no force or effect (S. 3461), S120 [10JA], S272 [18JA]

Republican Party: national agenda, S4942 [22SE]

Senate: legislative priorities, S2135 [26AP]

——— prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (S. Res. 631), S2473–S2476 [12MY]

——— prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (S. Res. 631), unanimous-consent request, S2475 [12MY]

——— tribute to staff working on H.R. 5376, Inflation Reduction Act, S4953 [22SE]

Sports: improve integrity and safety of horseracing by requiring uniform anti-doping and medication control program enforced by independent Horseracing Integrity and Safety Authority, S9765 [21DE]

U.S.-China Economic and Security Review Commission: implement recommendations relative to countering China’s influence in Latin America and the Caribbean, S405 [31JA]

Warren, Senator: tribute to staff working on H.R. 5376, Inflation Reduction Act, S4470 [7SE]

Reports filed

Advanced Research Project Agency-Health (ARPA-H) Act: Committee on Energy and Commerce (House) (H.R. 5585) (H. Rept. 117–365), H5485 [13JN]

Consideration of H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act: Committee on Rules (House) (H. Res. 1191) (H. Rept. 117–381), H5733 [21JN]

Consideration of H.R. 6833, Affordable Insulin Now Act: Committee on Rules (House) (H. Res. 1017) (H. Rept. 117–285), H4071 [31MR]

Consideration of H.R. 7007, Supplemental Appropriations for Coronavirus Emergency Response and Relief: Committee on Rules (House) (H. Res. 973) (H. Rept. 117–269), H1421 [9MR]

Consideration of Senate Amendment to H.R. 5376, Inflation Reduction Act: Committee on Rules (House) (H. Res. 1316) (H. Rept. 117–451), H7707 [12AU]

Direct President To Provide Documents With Several Agencies on Recommendations To Reduce Availability of Illicitly Manufactured Fentanyl-Related Substances: Committee on Energy and Commerce (House) (H. Res. 1274) (H. Rept. 117–527), H8313 [29SE]

Direct Sec. of HHS To Provide Documentation to House of Representatives Relative to Negotiation of Prices for Prescription Drugs Under Prescription Drug Program: Committee on Energy and Commerce (House) (H. Res. 1284) (H. Rept. 117–534), H8369 [30SE]

Disaster Assistance Simplification Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 4599) (S. Rept. 117–163), S5051 [27SE]

Enhancing DHS Drug Seizures Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 4645) (S. Rept. 117–221), S6962 [5DE]

FDA Safety and Landmark Advancements (FDASLA) Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 4348), S3269 [13JY]

Fighting Emerging Narcotics Through Additional Nations To Yield Lasting (FENTANYL) Results Act: Committee on Foreign Relations (Senate) (S. 1160), S2939 [14JN]

Kids First Research Act 2.0: Committee on Energy and Commerce (House) (H.R. 623) (H. Rept. 117–431), H7072 [22JY]

Pharmacy Benefit Manager Transparency Act: Committee on Commerce, Science, and Transportation (Senate) (S. 4293), S7199 [14DE]

Prevent Exposure to Narcotics and Toxics (PREVENT) Act: Committee on Homeland Security (House) (H.R. 5274) (H. Rept. 117–375), H5684 [17JN]

Request President and Direct Sec. of HHS To Transmit Documents to House of Representatives Relative to Any Coronavirus Vaccine: Committee on Energy and Commerce (House) (H. Res. 1244) (H. Rept. 117–516), H8219 [28SE]

Request President and Direct Sec. of HHS To Transmit Documents to House of Representatives Relative to Ivermectin: Committee on Energy and Commerce (House) (H. Res. 1355) (H. Rept. 117–529), H8313 [29SE]

Revise and Extend FDA User-Fee Programs for Prescription Drugs, Medical Devices, Generic Drugs, and Biosimilar Biological Products: Committee on Energy and Commerce (House) (H.R. 7667) (H. Rept. 117–348), H5331 [7JN]

Rulings of the Chair

Economy: use of budget reconciliation to fight inflation, reduce prescription drug and health care costs, address climate change, increase tax fairness, and reduce deficit (H.R. 5376), S4197 [6AU]

Statements

Affordable Insulin Now Act: Adam Brandon, FreedomWorks (organization), H4040 [31MR]

——— National Taxpayers Union, H4040 [31MR]

FDA User-Fee Programs for Prescription Drugs, Medical Devices, Generic Drugs, and Biosimilar Biological Products Goals and Procedures: Xavier Becerra, Sec. of HHS, S5177–S5220 [28SE]

Tables

Distributional effects of certain Inflation Reduction Act provisions: Committee on Taxation (Joint), H7655–H7657 [12AU]

Estimated pay-as-you-go effects of H.R. 7667, revise and extend FDA user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, H5330 [7JN]

Texts of

H. Res. 973, consideration of H.R. 7007, supplemental appropriations for coronavirus emergency response and relief, H1390 [9MR]

H. Res. 1017, consideration of H.R. 6833, Affordable Insulin Now Act, H4023 [31MR]

H. Res. 1191, consideration of H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act, H5745 [22JN]

H. Res. 1316, consideration of Senate amendment to H.R. 5376, Inflation Reduction Act, H7561 [12AU]

H.R. 623, Kids First Research Act 2.0, H7124 [26JY], H7198, H7223 [27JY]

H.R. 5274, Prevent Exposure to Narcotics and Toxics (PREVENT) Act, H5693 [21JN]

H.R. 5376, Inflation Reduction Act, H7577–H7646 [12AU]

H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act, H5795–H5798 [22JN]

H.R. 5657, Medical Marijuana Research Act, H4136–H4138 [4AP]

H.R. 6833, Affordable Insulin Now Act, H4033 [31MR]

H.R. 7667, revise and extend FDA user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, H5298–H5319 [7JN]

H.R. 8454, Medical Marijuana and Cannabidiol Research Expansion Act, H7120–H7122 [26JY]

S. 854, Methamphetamine Response Act, H1156 [28FE]

S. 1662, Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act, H1159 [28FE]

S. 2796, Rural Opioid Abuse Prevention Act, H8745 [5DE]

S. 4235, amend Controlled Substances Act to fix technical error in definitions, S4625 [14SE]

S. 4315, Protecting America From Narcotics and Illicit Chemicals (PANIC) Act, S2754 [26MY]

S. 5002, FDA Modernization Act 2.0, S5514 [29SE]

S. Res. 602, National Adult Hepatitis B Vaccination Awareness Day, S2222 [28AP]

S. Res. 624, National Fentanyl Awareness Day, S2383 [9MY]

S. Res. 631, prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages, S2495 [12MY]

S. Res. 657, Older Americans Mental Health Awareness Day, S2759 [26MY]

S.J. Res. 32, disapprove Centers for Medicare & Medicaid Services rule entitled ‘‘Medicare and Medicaid Programs; Omnibus COVID–19 Health Care Staff Vaccination’’, S936 [2MR]

S.J. Res. 39, disapprove Dept. of HHS rule entitled ‘‘Vaccine and Mask Requirements To Mitigate the Spread of COVID–19 in Head Start Programs’’, S675 [14FE], S2265 [3MY]